Shenzhen MABSKY Biotechnology Co., Ltd.

Shenzhen MABSKY Biotechnology Co., Ltd. (English abbreviation "MABSKY") was established in 2004. It is a high-tech enterprise specializing in molecular IVD reagents and solutions. Its main product series include six major categories: food safety, respiratory diseases, intestinal diseases, vector-borne infectious diseases, animal diseases, and public health, with nearly 300 testing products (including recently prevalent SARS-CoV-2, Ebola, Zika, and African Swine Fever) and 17 authorized invention patents. It has obtained 7 national Class III approvals and 22 Class II approvals, passed the NFDA 13485 in vitro diagnostic production quality assessment and NQA 9001 quality system certification, and some key new products have obtained EU CE registration. Over the past decade, the company has been committed to hard work and striving! It has been making efforts to achieve breakthroughs in global major infectious diseases and malignant common diseases such as tumors. In recent years, innovation investment, operating revenue, and talent introduction have maintained rapid growth. After the headquarters moved to Shenzhen International Innovation Valley at the end of 2020, it has established 25 provincial-level offices targeting the domestic markets of disease control, quarantine, and quality supervision, and has basically covered municipal and district-level units. It has become a mature industrialization platform in the field of molecular diagnostics in the biopharmaceutical industry. It is believed that in the near future, under the leadership training of the Mindray Group, MABSKY will become an outstanding enterprise in the Guangdong-Hong Kong-Macao Greater Bay Area and the group's business segment.